Mark D. Erickstad, M. Paul Brian Williams, M. University Dr. Huong T. Hegde, M. Michael G. Wierschem, M. Mitchell Owen Moskowitz, M. Allan C. Steven Sukin, M. Texas Urology Specialists-Webster W. Medical Center Blvd. How the Test is Performed. A blood sample is needed. How to Prepare for the Test. How the Test will Feel. Why the Test is Performed. Reasons for a PSA test: This test may be done to screen for prostate cancer.
It is also used to follow people after prostate cancer treatment to see if the cancer has come back. If a provider feels the prostate gland is not normal during physical exam. Ask about: Whether screening decreases your chance of dying from prostate cancer Whether there is any harm from prostate cancer screening, such as side-effects from testing or overtreatment of cancer when discovered Men younger than age 55 have a higher chance of developing prostate cancer and should talk with their provider about PSA screening if they: Have a family history of prostate cancer especially a brother or father Are African American.
Older men often have slightly higher PSA levels than younger men. What Abnormal Results Mean. A high PSA level has been linked to an increased chance of having prostate cancer. Other conditions can cause a rise in PSA, including: A larger prostate Prostate infection prostatitis Urinary tract infection Recent tests on your bladder cystoscopy or prostate biopsy Catheter tube recently placed into your bladder to drain urine Recent intercourse or ejaculation Recent colonoscopy Your provider will consider the following things when deciding on the next step: Your age If you had a PSA test in the past and how much and how fast your PSA level has changed If a prostate lump was found during your exam Other symptoms you may have Other risk factors for prostate cancer, such as ethnicity and family history Men at high risk may need to have more tests.
These may include: Repeating your PSA test, most often sometime within 3 months. You may receive treatment for a prostate infection first. A prostate biopsy will be done if the first PSA level is high, or if the level keeps rising when the PSA is measured again. This measures the percentage of PSA in your blood that is not bound to other proteins.
The lower the level of this test, the more likely it is that prostate cancer is present. Other tests may also be done. In Scotland : you can complain to your local health board. The Patient Advice and Support Service can provide information, advice and support. Get more information from NHS Inform. In Wales : you can complain to your local health board. Your local Community Health Council can help with this. Health in Wales has more information. The Patient and Client Council can provide advice and support.
Get more information from nidirect. What is a baseline PSA test? There is currently no screening programme for prostate cancer in the UK. List of references. Urol Clin North Am. The Lancet. January Obesity and Prostate Cancer: Weighing the Evidence. Eur Urol. Clin Cancer Res. Prostatitis and its Management. Eur Urol Suppl. Published Accessed January 4, Board of Community Health Councils. NHS Complaints procedure - how we can help.
Accessed July 29, Cancer Research UK. Cancer incidence for common cancers Accessed December 12, Prostate cancer incidence statistics: by age Prostate cancer incidence statistics: Lifetime risk of prostate cancer Accessed July 6, Cao Y, Ma J. Cancer Prev Res Phila Pa. Acute Bacterial Prostatitis: Diagnosis and Management. Am Fam Physician. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT Prostate testing for cancer and Treatment study.
BJU Int. Genetic markers a landscape in prostate cancer. Mutat Res Mutat Res. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol. September The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. Clin Genitourin Cancer. Am J Roentgenol. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens.
Prospective study on metabolic factors and risk of prostate cancer: Metabolic Factors and Prostate Cancer. Prostate cancer screening with prostate-specific antigen PSA test: a systematic review and meta-analysis.
Jones AL, Chinegwundoh F. Update on prostate cancer in black men within the UK. March Talking about Your Advanced Cancer. Planning for Advanced Cancer. Advanced Cancer and Caregivers. Questions to Ask about Advanced Cancer. Managing Cancer Care. Finding Health Care Services. Advance Directives. Using Trusted Resources. Coronavirus Information for Patients. Clinical Trials during Coronavirus. Adolescents and Young Adults with Cancer.
Emotional Support for Young People with Cancer. Cancers by Body Location. Late Effects of Childhood Cancer Treatment. Pediatric Supportive Care. Rare Cancers of Childhood Treatment. Childhood Cancer Genomics. Study Findings. Metastatic Cancer Research. Intramural Research. Extramural Research. Cancer Research Workforce. Partners in Cancer Research.
What Are Cancer Research Studies. Research Studies. Get Involved. Cancer Biology Research. Cancer Genomics Research. Research on Causes of Cancer. Cancer Prevention Research. Cancer Treatment Research. Cancer Health Disparities. Childhood Cancers Research. Global Cancer Research. Cancer Research Infrastructure. Clinical Trials. Frederick National Laboratory for Cancer Research. Bioinformatics, Big Data, and Cancer. Annual Report to the Nation.
Research Advances by Cancer Type. Stories of Discovery. Milestones in Cancer Research and Discovery. Biomedical Citizen Science. Director's Message. Budget Proposal. Stories of Cancer Research. Driving Discovery.
Highlighted Scientific Opportunities.
0コメント